These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 12479884)
1. Monitoring of unfractionated heparin with the activated partial thromboplastin time: determination of therapeutic ranges. van den Besselaar AM; Sturk A; Reijnierse GL Thromb Res; 2002 Sep; 107(5):235-40. PubMed ID: 12479884 [TBL] [Abstract][Full Text] [Related]
2. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin. Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794 [TBL] [Abstract][Full Text] [Related]
3. The PiCT Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411 [TBL] [Abstract][Full Text] [Related]
4. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation. Toulon P; Smahi M; De Pooter N J Thromb Haemost; 2021 Aug; 19(8):2002-2006. PubMed ID: 33555096 [TBL] [Abstract][Full Text] [Related]
5. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Bates SM; Weitz JI; Johnston M; Hirsh J; Ginsberg JS Arch Intern Med; 2001 Feb; 161(3):385-91. PubMed ID: 11176764 [TBL] [Abstract][Full Text] [Related]
6. Establishing a new target range for unfractionated heparin for acute coronary syndromes. Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747 [TBL] [Abstract][Full Text] [Related]
7. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Vandiver JW; Vondracek TG Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940 [TBL] [Abstract][Full Text] [Related]
8. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study. Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025 [TBL] [Abstract][Full Text] [Related]
9. [Correlation between aPTT and antifactor Xa to determine therapeutic ranges for unfractionated heparin]. Mariné L; Sánchez G; Vargas JF; Zúñiga P; Aizman A; Mertens R; Bergoeing M; Muñoz B Rev Med Chil; 2014 Nov; 142(11):1392-7. PubMed ID: 25694284 [TBL] [Abstract][Full Text] [Related]
10. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506 [TBL] [Abstract][Full Text] [Related]
11. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring. Vandiver JW; Vondracek TG Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756 [TBL] [Abstract][Full Text] [Related]
12. [Comparison of heparin-induced prolongation of APTT in 12 different laboratories in Kyushu area]. Tanaka N; Manabe M; Yamashita S; Ikeda K; Obayashi K; Uchiba M; Ando Y Rinsho Byori; 2013 Jul; 61(7):576-82. PubMed ID: 24205697 [TBL] [Abstract][Full Text] [Related]
14. Establishing an institution-specific therapeutic range for heparin. Volles DF; Ancell CJ; Michael KA; Mullins DM; Humphries JE Am J Health Syst Pharm; 1998 Oct; 55(19):2002-6. PubMed ID: 9784787 [TBL] [Abstract][Full Text] [Related]
15. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Kitchen S; Preston FE Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715 [TBL] [Abstract][Full Text] [Related]
16. Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients. Rosborough TK Am J Clin Pathol; 1997 Dec; 108(6):662-8. PubMed ID: 9384448 [TBL] [Abstract][Full Text] [Related]
17. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin. Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169 [TBL] [Abstract][Full Text] [Related]
18. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support. Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404 [TBL] [Abstract][Full Text] [Related]
19. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin. Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751 [No Abstract] [Full Text] [Related]
20. Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics. Trucco M; Lehmann CU; Mollenkopf N; Streiff MB; Takemoto CM J Thromb Haemost; 2015 May; 13(5):788-94. PubMed ID: 25740425 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]